Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data

Table 3 Association of hypoglycemic events with glycemia medication class ⁽¹⁾

	Intensive Glycemia			Standard Glycemia
Medication class	Person yrs of use of medication or combination	# of HMA events associated medication use	# events per 100 Person yrs	Person yrs of use of medication or combination	# of HMA events associated medication use	# events per 100 Person yrs
All Cases	17141.4	547	3.19	17709.9	185	1.04
Combination of medication classes
Oral medication only ⁽²⁾	5691.6	110	1.93	9202.7	18	0.20
Metformin, TZD ⁽³⁾	10342.1	300	2.90	5179.3	46	0.89
Metformin, Sulfonylurea, TZD ⁽⁴⁾	6073.3	165	2.72	3360.7	18	0.54
Insulin only ⁽⁵⁾	705.6	43	6.09	1476.6	39	2.64
Insulin plus metformin	8853.8	293	3.31	5116.1	82	1.60
Insulin plus insulin sensitizer ⁽⁶⁾	10271.5	379	3.69	5991.6	111	1.85
Insulin plus secretagogue ⁽⁷⁾	6747.5	226	3.35	3609.0	59	1.63

⁽¹⁾ participant reported a hypoglycemic event while taking the medication.
⁽²⁾ any combination of oral medications but no insulin.
⁽³⁾ metformin + TZD, regardless of other medications.
⁽⁴⁾ metformin + TZD + sulfonylurea, regardless of other medications.
⁽⁵⁾ any combination of insulin but no oral medications.
⁽⁶⁾ insulin sensitizer = TZD, metformin.
⁽⁷⁾ insulin secretogogues = sulfonylurea, meglitinides (prandin), incretins (exenatide).

ISSN: 1472-6823